Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid by Bryan J Heard et al.
Heard et al. BMC Musculoskeletal Disorders 2012, 13:126
http://www.biomedcentral.com/1471-2474/13/126RESEARCH ARTICLE Open AccessMatrix metalloproteinase protein expression
profiles cannot distinguish between normal and
early osteoarthritic synovial fluid
Bryan J Heard1,4, Liam Martin1,4, Jerome B Rattner2,4, Cyril B Frank3,4, David A Hart3,4 and Roman Krawetz2,3,4*Abstract
Background: Osteoarthritis (OA) and Rheumatoid arthritis (RA) are diseases which result in the degeneration of the
joint surface articular cartilage. Matrix Metalloproteinases (MMPs) are enzymes that aid in the natural remodelling of
tissues throughout the body including cartilage. However, some MMPs have been implicated in the progression of
OA and RA as their expression levels and activation states can change dramatically with the onset of disease. Yet, it
remains unknown if normal and arthritic joints demonstrate unique MMPs expression profiles, and if so, can the
MMP expression profile be used to identify patients with early OA. In this study, the synovial fluid protein
expression levels for MMPs 1, 2, 3, 7, 8, 9, 12 & 13, as well as those for the Tissue Inhibitors of MMPs (TIMPs) 1, 2, 3,
& 4 were examined in highly characterized normal knee joints, and knee joints with clinically diagnosed OA (early
and advanced) or RA. The purpose of this study was to determine if normal, OA, and RA patients exhibit unique
expression profiles for a sub-set of MMPs, and if early OA patients have a unique MMP expression profile that could
be used as an early diagnostic marker.
Methods: Synovial fluid was aspirated from stringently characterized normal knee joints, and in joints diagnosed
with either OA (early and advanced) or RA. Multiplexing technology was employed to quantify protein expression
levels for 8 MMPs and 4 TIMPs in the synovial fluid of 12 patients with early OA, 17 patients diagnosed with
advanced OA, 15 with RA and 25 normal knee joints. Principle component analysis (PCA) was used to reveal which
MMPs were most influential in the distinction between treatment groups. K – means clustering was used to verify
the visual grouping of subjects via PCA.
Results: Significant differences in the expression levels of MMPs and TIMPs were observed between normal and
arthritic synovial fluids (with the exception of MMP 12). PCA demonstrated that MMPs 2, 8 & 9 can be used to
effectively separate individuals diagnosed with advanced arthritis from early osteoarthritic and normal individuals,
however, these MMP profiles do not separate early OA from normal synovial fluid. An apparent separation between
advanced OA and RA subjects was also revealed through PCA. K-means clustering verified the presence of 3
clusters: normal joints clustered with early OA, and separate clusters of advanced OA or RA.
Conclusions: This study demonstrates that unique MMP and TIMP expression profiles are present within normal,
advanced OA and RA synovial fluid. These MMP profiles can be used to distinguish advanced OA & RA synovial
fluid from early OA & normal synovial fluid, and even between synovial fluid samples from OA and RA joints.
Although this methodology cannot be used for the diagnosis of early OA, high throughput multiplex technology of
MMPs and TIMPs in synovial fluid may prove useful in determining the severity of the disease state, and/or
quantifying the response of individuals to disease interventions.* Correspondence: rkrawetz@ucalgary.ca
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There are likely several clinically recognized arthritic
phenotypes, however, broadly speaking there are two
main ‘types’ of arthritis: RA, a chronic inflammatory dis-
ease characterized by joint swelling, joint tenderness,
and destruction of synovial joints [1] and OA, a hetero-
geneous group of conditions that lead to joint symptoms
and signs which are associated with the defective integ-
rity of articular cartilage [2]. Given the presence of auto-
antibodies to a number of proteins such as citrullinated
peptides (CP) and immunoglobulin (i.e. rheumatoid fac-
tor: RF) [1], RA has been appropriately classified as an
autoimmune disease. There are a number of validated
diagnostic tools and criteria that can predict the onset of
RA, in some cases years before overt clinical manifesta-
tions. However, in the case of OA, no known (validated)
early diagnostic test exists that can either predict the
onset or eventual severity of the disease. To this end, a
number of studies have used structural fragments of car-
tilage proteins as potential biomarkers of OA. Procolla-
gen II C-propeptide upregulation, a precursor of COL II
that appears as a repair response to damaged cartilage,
has been localized in the articular cartilage of patients
diagnosed with early OA [3]. Studies have shown this
up-regulation is detectable in patient synovial fluid and
serum, thus highlighting it as a potential biomarker for
early OA [3]. Conversely, proteolytic COL II breakdown
is key in the cartilage erosion witnessed in arthritic dis-
eases. Fragments of COL II or COL II epitopes have also
been highlighted as potential OA biomarkers, generally
falling into one of three potential categories based on
their origin from the native COL II molecule: cleavage
neoepitopes, denaturation epitopes, or epitopes from the
mature end of the molecule [4]. To date, however, no
COL II/ProCOL II early OA diagnostic assays have
entered the market due to the variability of COL II epi-
topes within normal and arthritic patient populations.
Other historical biomarkers such as cartilage oligomeric
protein (COMP) and hyaluronan (HA) [5,6] have also
been identified as early biomarkers, but have not been
clinically adopted. More recently, profiling of the inflam-
matory response in OA patients is being investigated,
however, this area of study is still in need of further in-
vestigation [7,8]. Clinically speaking, only when evidence
of joint space narrowing, cartilage loss, or osteophyte
formation is obtained can the disease be clinically diag-
nosed in its later stages [2]. In this capacity, matrix
metalloproteinases (MMPs) have been studied as poten-
tial indicators of the onset of arthritis as MMPs have
been implicated in the loss of articular cartilage which
occurs both in OA and RA [9,10].
The chondrocyte extracellular matrix (ECM) of healthy
and arthritic joints is constantly subjected to remodelling
processes [11,12]. This delicate balance betweenanabolism and catabolism of ECM components is
mediated by interactions with synthetic and degradative
molecules present in the joint environment (synovial
fluid). In arthritic conditions, it is hypothesised that for
some reason the catabolic potential within the joint envir-
onment overrides the anabolic, resulting in irreversible de-
struction within the joint. Many proteolytic enzymes have
the ability to degrade the articular cartilage collagen scaf-
fold including several of the MMPs [13,14], as well as
non-MMPs. MMPs are a family of tissue remodeling
enzymes which, when activated, recognize specific
sequences in ECM proteins and then cleave these proteins.
MMP-1 is an interstitial collagenase (collagenase 1) pro-
duced mainly (but not exclusively) by synovial cells within
the joint. MMP-1 efficiently degrades collagen types I and
III during fibrolytic tissue remodeling, while also main-
taining the ability to degrade type II collagen. MMP-2 is a
gelatinase (gelatinase A) that is secreted by stromal cells
beneath the synovial lining [15]. This MMP has the ability
to degrade aggrecan, and extracellular matrix proteogly-
can, as well as collagen types I, II, and III using a similar
mechanism to MMPs of the collagenase subfamily. MMP-
3 is a stromelysin (stromelysin 1) with a specificity to fa-
cilitate degradation of extracellular matrix proteoglycans
such as versican and aggrecan. MMP-7, matrilysin, has
been show to cleave proteoglycans and collagen III/IV/V/
IX/X/XI when present in its active form [16]. MMP 7 in
its active form has also been shown to activate pro-MMPs
1, 2, and 7 [16]. MMP-8, neutrophil collagenase, is
secreted by neutrophils and MMP-9, gelatinase-B, is also
secreted by neutrophils in addition to macrophages and
synovial cells [15]. MMP-12, a metalloelastase secreted by
macrophages, has the ability to breakdown collagen type
IV, and proteoglycan, as well as various other ECM com-
ponents [17]. MMP-13 is a collagenase (collagenase 3)
produced by chondrocytes and has specificity for type II
collagen, while to a lesser extent also degrades collagen
types I and III as well as aggrecan. MMPs are inhibited by
specific endogenous tissue inhibitors of metalloproteinases
(TIMPs), which consist of four protease inhibitors:
TIMP1, TIMP2, TIMP3 and TIMP4. Each TIMP binds
with differential rates of interaction and affinity to a MMP,
(1:1, 2:2 stoichiometry). TIMP-1 inhibits MMP-1, MMP-3
and MMP-9 [18-21]. TIMP-2 inhibits proMMP-2 [18,22],
however, TIMP-2 also has a bi-functional effect on
MMP-2 since proMMP-2 activation requires low levels of
TIMP-2 for activation, whereas a greater concentration of
TIMP-2 inhibits MMP-2 [23]. TIMP-3 inhibits MMP-2
and MMP-9 [24], whereas TIMP-4 is a good inhibitor for
all classes of MMPs without remarkable preference for
specific MMPs [25].
In this study, the concentrations of specific MMPs (1,
2, 3, 7, 8, 9, 12, and 13) were quantified in the synovial
fluid collected from normal joints and joints from
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advanced) or RA. Through PCA and K – means cluster-
ing analysis, reproducible and unique MMP expressions
profiles were identified for normal, OA (advanced) and
RA synovial fluid, however, normal and early OA syn-
ovial fluid cannot be distinguished from each other using
this methodology. Utilizing high-through-put multiplex-
ing methodologies with multi-variant statistical analysis
allows for the visualization of changes within a certain
marker between/within groups, but also provides the op-
portunity to observe if the interaction of many markers
can better describe a phenotype of arthritic disease. This
is of significance as distinct MMP profiles of disease
may be exploited for alternative diagnostics as well as




Informed consent to participate was obtained by written
agreement. The study protocol was approved by the
University of Calgary Research Ethics Board (Application
number: 21987).
Inclusion and Exclusion Criteria
Early OA Group: Inclusion criteria was early OA diag-
nosed based on arthroscopic examination, these patients
had an Outerbridge score of under grade 2 (a partial-
thickness defect with fissures on the surface that do not
reach sub-chondral bone or exceed 1.5 cm in diameter),
all but one patient was over 40 years of age. Advanced
OA Group: Inclusion criteria were an age of 40 years or
older, OA diagnosed based on the American College of
Rheumatology [2] criteria with X-ray documentation,
and no evidence of autoimmune disease or RA.RA
Group: Inclusion criteria were an age of 40 years or
older, RA diagnosed based on the American College of
Rheumatology criteria [1].
Normal Group: Inclusion criteria for control cadaveric
donations (collected at the Southern Alberta Organ and
Tissue Donation Program (SAOTDP)) were an age of
40 years or older, no history of arthritis, joint injury or
surgery (including visual inspection of the cartilage sur-
faces during recovery), no prescription anti-
inflammatory medications, no co-morbidities (such as
diabetes/cancer), and availability within 4 hrs of death.
Subjects
Early OA Group: Twelve patients (11 males, ages: 31,
43, 46, 46, 49, 50, 52, 54, 58, 59, 66 / 1 female, age: 49)
diagnosed with early osteoarthritis had synovial fluid
aspirated prior to the arthroscopic examination without
lavage (Table 1) (University of Calgary Ethics # 21987).Advanced OA Group: Seventeen patients (8 males,
ages: 45, 51, 57, 62, 65, 68, 68, 75 / 9 females, ages: 43,
49, 52, 55, 58, 62, 64, 73, 74) diagnosed with osteoarth-
ritis had synovial fluid aspirated during routine medical
visits without lavage (Table 1) (University of Calgary
Ethics # 21987).
RA Group: Fifteen patients (5 males, ages: 40, 48, 51,
55, 55 / 10 females, ages: 40, 48, 49, 52, 54, 54, 61, 63,
75) diagnosed with Rheumatoid arthritis had synovial
fluid aspirated during routine medical visits without lav-
age (Table 1)( University of Calgary Ethics # 21987).
Normal Control Group: Thirty fresh cadaveric dona-
tions were recovered within 4 hours from time of death
through the SAOTDP (University of Calgary Ethics #
21987). Synovial fluid was collected from the remaining
25 normal individuals without lavage (14 males, ages: 40,
47, 50, 52, 54, 54, 56, 58, 65, 65, 68, 69, 72, 77 / 11
females, ages: 42, 46, 48, 50, 51, 51, 52, 65, 65, 68, 75,
78) (Table 1).
Synovial Fluid
Synovial fluid from control individuals was obtained by
the SAOTDP. Synovial fluid from advanced OA and RA
patients was aspirated from the knee joint by the attend-
ing Rheumatologist using conventional sterile technique.
The early OA synovial fluid was recovered by an ortho-
pedic surgeon under sterile conditions. All synovial fluid
samples were collected without the use of lavage or any
other diluant. The native synovial fluid samples were ali-
quoted and stored in cryogenic vials at -800 C after cells
were removed by centrifugation at 40 C. For
standardization of the protocol, all synovial fluid samples
were subjected to only one freeze-thaw event prior to
the assessment.
ELISA and Luminex Multiplex Array
Synovial fluid aliquots were thawed on ice and 20 μl of
fluid was diluted 1:5 with the Milliplex running buffer
(Millipore, Billercia, MD). Sample analysis was per-
formed by Eve Technologies (University of Calgary)
using the Fluorokine MAP Multiplex Human MMP
Panel (R&D Systems, Minneapolis, MN) and the Lumi-
nex 100 platform (Luminex Corp., Austin, TX), accord-
ing to the manufacture’s instruction, as well as
previously published methods [26]. All samples were
prepared and analyzed according to the manufacturer’s
instructions included with the kits. All samples were
assessed at least in duplicate and prepared standards
were included in all runs. Briefly, MMP-specific anti-
bodies are pre-coated onto color-coded micro-particles.
These micro-particles along with standards and samples
added to the plate and the immobilized antibodies bind
the MMPs of interest. After washing away any unbound
substances, biotinylated antibodies specific to the MMP
Table 1 Summary of normal, early OA, OA, and RA individuals
Patient Group Age Sex Clinical Diagnosis Prescribed Medication
Early Osteoarthritis (n=12) 58 M Left knee N/A
43 M right knee N/A
43 M right knee N/A
49 F right knee N/A
49 M right knee N/A
66 M right knee N/A
54 M Left knee N/A
59 M Left knee N/A
50 M right knee N/A
46 M right knee N/A
46 M right knee N/A
31 M right knee N/A
52 M right knee N/A
Osteoarthritis (n=17) 51 M OA Left knee N/A
57 M OA Left knee N/A
62 M OA Left knee N/A
68 M OA Both Knees & Spine N/A
75 M OA Both Knees & Spine N/A
52 F OA Right knee N/A
55 F OA Right knee N/A
64 F OA Left knee N/A
73 F OA Left knee N/A
74 F OA Both Knees N/A
65 M OA Both Knees N/A
68 M Knee & Both Hands N/A
62 F Left Knees N/A
58 F Both Knees & Spine N/A
49 F Right Knee N/A
43 F Both Knees N/A
45 M Right Knee N/A
Rheumatoid Arthritis (n=15) 40 M RA Infiximab
51 M RA Leftlunomide
55 M RA N/A
40 F RA Methotrexate, Plaquenil, Abatacept
48 M RA N/A
49 F RA Methotrexate
54 F RA Abatacept
61 F RA N/A
75 F RA Hydrochloroquine, Naproxen
75 M RA Prednisone
52 M RA N/A
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Table 1 Summary of normal, early OA, OA, and RA individuals (Continued)
54 M RA Methotrexate
48 M RA Abatacept
63 M RA Abatacept
55 M RA Methotrexate
Normal (n=25) 58±11 14M, 11F Normal Joint – No prescribed medications.
Synovial fluid was aspirated from the knees of normal individuals and patients with OA or RA. The age, sex, afflicted joint(s) and prescribed medication are
presented above.
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remove any unbound biotinylated antibody,
Streptavidin-PE antibodies were added to each well. A
final wash removed unbound Streptavidin-PE and the
micro-particles were resuspended in buffer and read
using the Luminex 100 analyzer. ELISA’s were preformed
on normal (n = 10), early OA (n = 10), advanced OA
(n= 10) and RA (n= 10) synovial fluid samples to measure
the total protein amounts (pro and active) of MMP 9
and 13 using commercially available kits (Anaspec,
Freemont CA) according to the manufactures instruc-
tions. Each sample was assayed in duplicate and the
concentration was extrapolated from the included
standards.Statistical Analysis
Statistical analysis was facilitated by Stata 9.2 for Macin-
tosh (Stata, College Station, TX) and Prism GraphPad 5
for Macintosh (Prism, La Jolla, CA). Treatment group
comparisons for MMPs and TIMPs of normal (n = 25),
early OA (n = 12), OA (n = 17), and RA (n = 15), were
made using the Kruskal-Wallis test with Dunn’s multiple
comparisons test. Principal component analysis (PCA)
was executed on all arthritic patients (early OA, OA and
RA) and normal control samples, a total of 69 records
within the data set in which factor loadings were calcu-
lated for MMP-1, 2, 3, 7, 8, 9, 12, and 13. Principal com-
ponents were retained if their Eigen value was greater
than or equal to 1 (in this case 3 components were
retained). To mathematically verify the visual groupings
of patients of each of the four treatment groups pre-
sented by PCA, K-Means clustering was implemented
using the first three principal components as inputs. K –
Means clustering is an unguided algorithm that sepa-
rates data into a predetermined number of groups (k
groups). This is accomplished through an iterative
process that calculates the shortest distance in space be-
tween 3 randomly selected centoids, then allocates each
sample accordingly. The distances are calculated based
on the multivariate data that can be associated with each
sample. In our study, each sample was represented by
three data points, the first, second, and third principal
components. PCA is a data reduction algorithm that
produces components that represent ideally weightedvalues that are calculated from the contributions of all
MMPs investigated, while retaining much of the variabil-
ity of the data set.Results
Group Comparison
Multiplex analysis was undertaken on synovial fluid
samples from normal, early OA, OA and RA joints to in-
vestigate protein expression levels of MMPs (Figure 1)
and TIMPs (Figure 2). Investigation of MMP protein ex-
pression levels (Figure 1) revealed a significant difference
in MMP 3 when normal samples were compared to early
OA samples. MMP 1, 2, 3, 8, and 13 expression levels
were significantly elevated in advanced OA samples
when compared to early OA samples, while also signifi-
cantly elevated when compared to MMP 1, 2, 7, 8, 9,
and 13 expression levels of normal synovial fluid sam-
ples. When RA MMP levels were compared to normal
MMP synovial fluid levels, significant elevations of
MMP 1, 3, and 8 were observed within the RA samples.
Finally, MMP 7 expression was significantly decreased in
RA samples compared to OA samples. Since multiplex
analysis is a relatively new methodology and a number
of studies have validated the accuracy of the approach,
some discrepancies have also been observed between
multiplex assays and ELISA [26-30]. Therefore, analysis
was conducted on MMP 9 and 13 to verify the trend of
expression levels across treatment groups as reported by
Luminex multiplexing to those detected by ELISA. With
the exception of Luminex being more sensitive to MMP
9 & 13 in advanced OA synovial fluid (although the
medians are similar, black bars within each treatment
group), the expression trends (and medians) appear the
same in each of the quantification methodologies
(Figure 3).
Since the assays (both multiplex and ELISA) detected
total MMP levels (active and pro forms) it was decided
to assay for the levels of TIMPs (tissue inhibitors of
metalloproteinases) in all synovial fluid samples to deter-
mine the expression profile of MMP inhibitors present
under normal and arthritic conditions. Investigation of
TIMP protein expression levels (Figure 2) revealed a sig-
nificant increase in expression level when RA samples
were compared to normal samples (TIMP 2), early OA
Figure 1 Comparison of MMP protein expression within the synovial fluid of Normal (n = 25), Early OA (n = 12), advanced OA (OA)
(n = 17), and RA (n= 15) patients. Significant differences indicated by bars connecting treatment groups. Box and whisker plot using Tukey’s
method, individual dots represent outliers. Significance accepted at p< 0.05.
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2). Advanced OA sample expression levels were elevated
when compared to early OA samples for TIMP 1, and 3.
Although a number of significant differences in MMP
protein expression were observed between normal, early
OA, advanced OA and RA synovial fluid, variation was
observed within the MMP expression panels of subjectswithin the four groups. Therefore principle component
analysis was used to determine how MMP levels could
be weighted towards specific joint disease states.
Principal Component Analysis
PCA was performed on the quantified MMP concentra-
tion data obtained from the multiplex analysis. It was
Figure 2 Comparison of TIMP protein expression within the
synovial fluid of Normal (n = 25), Early OA (n= 12), advanced
OA (OA) (n = 17), and RA (n = 15) patients. Significant differences
indicated by bars connecting treatment groups. Box and whisker
plot using Tukey’s method, individual dots represent outliers.
Significance accepted at p< 0.05.
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into 3 principal components that maintained 78% of the
total variance of the data set (Table 2.A). Three visual
groupings of our patient data were apparent upon inter-
pretation of the score plot (Figure 4A.) of the first two
principal components (PC1, and PC2). These three
groups appear to represent a combination of normal and
early OA patients, as well as groups of OA and RA
patients separately. PC1 and PC2, represent 43% and
19% of data set variance respectively, additively account-
ing for 62% of the variation within the data set. The fac-
tor weights, or the loading of each MMP on PC1 and
PC2 (Table 2.A) suggest that MMP 2, 8, and 9 were the
most influential in separating arthritis samples (both OA
and RA) from each other, as well as from normal and
early OA synovial fluid samples, while MMP 1, 12, and
13 where the most influential in the vertical separation
of RA synovial fluid samples from OA samples. Through
the use of this statistical method, specific MMP profiles/
weights can be attributed to normal, early OA, OA and
RA synovial fluid samples. However, to verify the visual
groupings apparent in the score plot a clustering algo-
rithm was used to test if these profiles could be validated
to predict the joints state solely on the MMP expression
levels.
Clustering Analysis of MMP Expression Levels
Since distinct MMP expression profiles were observed in
normal, OA and RA synovial fluid from the PCA
(Figure 4A), these profiles were analyzed using a cluster-
ing algorithm to test the specificity of each MMP profile
(Figure 4B). Using PC1, PC2, and PC3 as ideally
weighted inputs, the K-means clustering algorithm was
set to look for 3 distinct clusters. This algorithm
returned a normal/early OA cluster (25 normal, 10 early
OA, and 2 advanced OA), a RA cluster (14 RA, 2 early
OA, and 6 advanced OA), and an advanced OA cluster
(advanced 9 OA, and 1 RA) (Figure 4B.). Thus, mathem-
atically verifying the visual grouping of data by PCA,
and suggesting that distinct MMP expression profiles
reside in normal / early OA, advanced OA, and RA knee
joints across a wide range of age and prescribed medica-
tion, with contributions from both males and females.
Since the normal and early OA groups appear to co-
localize on the PCA and clustering plots, a further valid-
ation/verification step was taken to confirm this result.
When examining the normal and early OA data
Figure 3 Qualitative comparison of MMP 9 and 13 protein expression levels returned by Luminex multiplexing and ELISA. Box and
whisker plot using Tukey’s method, individual dots represent outliers.
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normal and early OA synovial fluid MMP expression
profiles are indistinguishable from each other
(Figure 4C, loading values presented in Table 2.B).
Discussion
In this study, the levels of select MMPs and TIMPs were
compared in the synovial fluid of normal, early OA,
advanced OA and RA afflicted joints. It was demon-
strated using multiplex Luminex technology and PCA
that distinct MMP profiles are present in advanced OA
and RA samples. Previous studies have demonstrated
MMP 1, 3, and 9 are elevated in the synovial fluid of RA
patients compared to levels present in advanced OA
patients [15], however, conflicts in the comparison of
our results to previous studies need to be addressed. A
comparison to similar, previously published studies has
been provided in Table 3. Table 3 summarizes our
results, and then compares to the results of similar stud-
ies conducted by Kim et. al. [31], Yoshihara et. al. [15],
Matsuno et. al. [32], and Liu et. al. [17], that have also
investigated MMP profiles of late-stage OA and RA. Al-
though these studies did not investigate MMP expres-
sion in normal or early OA synovial fluid, they do
provide a valuable comparison between RA and OA ex-
pression profiles. Differences between our findings, and
those of others, have been highlighted in bold. We
detected a non-significant decrease of MMP 2expression in RA synovial fluid compared to advanced
OA synovial fluid, while Kim et al. [31] and Yoshihara
et al. [15] each reported increases. We were able to de-
tect a significant decrease of MMP 7 expression levels in
RA samples compared to advanced OA samples, how-
ever, no differences in MMP 7 expression were detected
in a study by Matsuno et. al. [32]. In contradiction to
Yoshihara et al., [15] our findings indicate that a trend
found within MMP 8 of RA synovial fluid samples was
less than what was present in advanced OA synovial
fluid. Finally, our investigation of MMP 13 revealed a
decrease in expression level within RA synovial fluid
compared to advanced OA, although not significant, a
finding opposite to that of Kim et al [31]. It is possible
that we were not able to report differences between RA
and advanced OA synovial fluid in MMP 3 and MMP 9
due to variation stemming from sample sizes and patient
selection. Furthermore, it is quite possible that patients
with differing levels of disease severity and/or activity
may yield conflicting results. A study by Maeda et al.,
demonstrated that synovial fluid MMP 1 levels corre-
lated strongly with joint inflammation in RA patients
[33]. In the current study, we have not quantified in-
flammatory mediators in the synovial fluid, however,
these studies are ongoing within our lab. The equal pos-
sibility exists, however, that the differences in the meth-
odology employed in our study compared to others may
have had an impact on the resulting data. The vast
Table 2 Summary of Principle Components Analysis,
Components and Factor Weights for normal, early OA,
advanced OA (OA) and RA






MMP PC1 PC2 PC3
MMP 0.2704 0.5714 -o.2679
MMP2 0.4037 -0.2209 -0.2829
MMP3 0.3665 0.416 -0.2448
MMP 7 0.2875 -0.1492 0.6697
MMP8 0.4962 -0.1641 -0.0277
MMP9 0.4130 0.0671 0.4098
MMP12 0.0239 0.5104 0.3486
MMP13 0.3599 -0.3706 -0.2225







MMP PC1 PC2 PC3 PC4
MMP1 -0.2668 0.5118 0.2046 0.2665
MMP2 -0.3357 0.5045 0.0452 0.0662
MMP3 0.1353 0.1077 0.6581 0.3545
MMP7 0.1996 0.4664 -0.1648 -.04650
MMP8 0.4399 0.2325 -0.2258 0.5606
MMP9 0.5954 0.0967 -0.2546 0.1539
MMP12 0.3143 0.3696 0.2386 -0.4688
MMP13 0.334 -0.2333 0.5685 -0.1580
Figure 4 (A.) Score plot of Principal component analysis on
MMP protein expression within the synovial fluid of all samples
collected (n = 69). 3 groupings of samples are visible along the axis
of component 1, normal control (CTRL) and early OA patients
appear grouped together while RA and advanced OA (OA) patients
appear to form separate groups. Along the axis of component 2
there is a less distinct separation of treatment groups, however RA
and OA appear to be separated with overlap form the normal and
early OA. (B.) K-Means clusters to verify the 3 potential groupings of
patients. Cluster 1 contains 25 normal, 10 early OA, and 2 OA
patients. Cluster 2 contains 14 RA, 2 early OA, and 6 OA patients.
Finally, Cluster 3 contains 9 OA and 1 RA patients. (C.) Score plot of
Principal component analysis on MMP protein expression within the
synovial fluid of only normal and early OA samples.
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fluid and serum/plasma uses ELISA, a method that can
detect small amount of soluble protein in suspension
[15,17,31,32]. Furthermore, when MMP 9 and 13 were
analyzed using ELISA we observed that the ELISA
detected higher amounts of each protein. It is important
to note that the R&D (Luminex) and Anaspec (ELISA)
kits do not utilize the same antibodies, however, at the
time of publication R&D did not supply ELISA kits for
MMP 9 & 13 that detect total protein. Based on our
comparison of Luminex to ELISA with MMP 9 & 13, it
appears that normal, early OA and RA quantification
was similar, however, in advanced OA there seemed to
be detected at a higher level using the R&D assay kit, yet
Table 3 Summary of RA and advanced OA (OA) Results and Comparison to Current Literature
MMP Comparison Our Result Current Literature References
1 RA vs OA + + Kim et. al (2011), Yoshihara et.al. (2000), matsuno et. al. (2001)
2 RA vs OA - + Kim et. al (2011), Yoshihara et. al. (2000)
3 RA vs OA ~ + Yoshihara et. al. (2000), Matsuno et.al. (2001)
7 RA vs OA -* ND Matsuno et.al. (2001)
8 RA vs OA - + yoshihara et.al. (2000)
9 RA vs OA - + Kim et. al (2001), Yoshihara et.al. (200), Matsuno et. al. (2001)
12 RA vs OA + + Liu et. al. (2004)
13 RA vs OA - + Kim et. al (2001),
+ = expression in RA samples is increased comppared to OA samples; - = expression in RA samples is decreased cpmpared to OA samples; ~ = no difference; * =
significant difference; ND= not detectable.
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ment group when examined with Luminex or ELISA. Al-
though ELISA is the ‘gold standard’, it still exhibits
certain limitations. For example, since most commer-
cially available ELISA kits using horse radish-peroxidise
(HRP) or alkaline phosphatase (AP) based detection,
each specific antibody is required to have its own well
and sample aliquot, which when assaying small volumes
of sample can lead to increased well to well variability.
The Luminex platform is capable of measuring the ex-
pression of 100 specific antibodies per well, resulting in
decreased signal artifacts per well, in addition to
increased specificity since two specific capture anti-
bodies per molecules are required to bind before quanti-
fication takes place. These properties present Luminex
as an ideal system for quantifying very small changes
(pico-gram levels) in protein levels in equally small sam-
ple volumes (micro-litre levels) in a high throughput
manner. Furthermore, the collection, storage and treat-
ment of synovial fluid were also variable between our
studies and those of others. Within the current study all
synovial fluid samples were aliquoted and frozen once at
-800 C, and no enzyme (hyaluronidase) treatment was
performed on the synovial fluid as we have observed this
can increase sample to sample variability based on the
age, time and freeze thaw number of the enzyme (data
not shown).
Compared to MMP research in synovial fluid, few
papers have examined and quantified TIMP protein ex-
pression in arthritic knee joints and compared this to
TIMP expression in normal synovial fluid. Within the
present study, no significant differences in TIMP expres-
sion (1, 2, 3, or 4) were detected between normal and
early OA synovial fluid, which is consistent with the
findings that normal and early OA synovial fluid could
not be segregated based on MMP expression levels
alone. Overall the published data seems to suggest that
TIMP levels do not increase significantly with the sever-
ity of OA [34,35], however, TIMP 1 levels decrease
within injured joints [36]. Based on results present hereand previous studies it would appear that the regulation
of MMPs by TIMPs may be important in the progres-
sion of disease, however, it also appears that it cannot be
clearly understood solely through the quantification
and/or ratio of MMPs to TIMPs.
Using the Luminex platform, MMP-1, 2, 3, 7, 8, 9, 12,
13 and TIMP-1, 2, 3, 4 synovial fluid protein levels were
quantified in normal, early OA, advanced OA and RA
joints. Although there may be some concern over using
cadaveric donations in this case, it was necessary to
completely define the joints as ‘normal’. In some studies,
patients requiring arthroscopic examination that do not
demonstrate obvious pathology are considered normal,
while in others synovial fluid is simply removed from
joints of individuals that have no outward symptoms of
arthritis.
For the present study, synovial fluid was chosen as
MMP expression within the joint may or may not be
correlated to that of serum/plasma [37-39]. Since cartil-
age degeneration of the knee takes place within the syn-
ovial boundary it makes sense to sample and test the
synovial fluid for up/down-regulation of MMPs in the
joint environment. Although cell sources of MMPs
within the joint vary, for example synoviocytes (MMP 1,
2), chondrocytes (MMP 3, 7, 13), neutrophils (MMP 8,
9) and macrophages (MMP 12), with significant redun-
dancy in expression of each MMP by multiple cell types,
the results presented in this study (on MMP expression)
correspond with previous cellular studies. Mature
macrophages expressing MMP 12 are equally repre-
sented in the synovial membrane and fluid of OA and
RA patients [40,41], and in both disease states are sig-
nificantly increased in number compared to normal syn-
ovial tissue [41], importantly though, MMP expression
levels within a given cell type can also change with dis-
ease state [17]. Recently, through FACS analysis of syn-
ovial fluid of OA and RA patients it was identified that
the levels of neutrophils are actually not significantly dif-
ferent [42]. Furthermore, past studies have demonstrated
that neutrophils in RA presented diminished phagocytic
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these results corroborate our MMP expression profiles
(specifically MMP 8, 9 and 13) and suggest that although
there are similar numbers of neutrophils in OA and RA,
they may be expressing less MMPs in RA synovial fluid.
In specific regards to MMP 2, a number of studies have
clearly demonstrated that more fibroblasts are present in
OA synovial fluid than RA in part validating this result
[41,44].
Although using MMP profiles within synovial fluid
cannot distinguish normal vs. early OA knee joints, this
methodology maybe applicable to drug/treatment test-
ing, since this approach is based on a number of mar-
kers, even if one of two are differentially regulated
within an individual, the overall profile of disease will
not be significantly affected depending on the number of
targets used. A number of MMP inhibitors have been
developed to treat arthritic diseases with little or no ef-
fect, however, using this approach the overall effect of
treatment (including related and ‘off ’ targets) per indi-
vidual profile could be determined using this high
throughput approach. This would allow researchers,
physicians and pharmaceutical companies to not only
examine the effect of a specific drug on a specific target,
but also visualize the effects more globally among a fam-
ily of targets, which could lead to more efficient treat-
ments for arthritis.
Conclusions
Although many studies have compared synovial fluid ex-
pression levels or protein to those of serum samples to
look for corresponding targets to be exploited as bio-
marker profiles, it may be unlikely that only one or two
proteins demonstrate reliable specificity with OA or RA.
Using the methodology outlined in this study, the rela-
tionship between expression levels of MMPs can be
merged into a single visual plot which allows for the reli-
able and reproducible identification of normal from dis-
eased joints, however, this methodology cannot
distinguish between normal and early OA synovial fluid,
suggesting that the ‘degradative snap shot’ of the early
OA joint may not be significantly different from that of
a healthily joint at the level of the MMPs analyzed.
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